黑素瘤-话题@MedSci

#黑素瘤#

41篇内容 | 2086人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2226984, encodeId=fffa2226984c7, content=<a href='/topic/show?id=364d4046940' target=_blank style='color:#2F92EE;'>#四环素类抗生素#</a> <a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=中南大学湘雅医院彭聪教授团队：揭示四环素类抗生素依拉环素通过促进M1型巨噬细胞极化增强黑素瘤抗PD1免疫治疗疗效的作用和机制, objectType=article, longId=844179, objectId=30128441e97c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719622163994_5579292.png, objectUrl=/article/show_article.do?id=30128441e97c, replyNumber=0, likeNumber=45, createdTime=2024-09-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=30128441e97c, moduleTitle=中南大学湘雅医院彭聪教授团队：揭示四环素类抗生素依拉环素通过促进M1型巨噬细胞极化增强黑素瘤抗PD1免疫治疗疗效的作用和机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30128441e97c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1479440, encodeId=2d8614e9440df, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=皮肤镜鉴别恶性黑素瘤, objectType=article, longId=735975, objectId=559ee35975f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=559ee35975f2, replyNumber=0, likeNumber=70, createdTime=2022-08-17, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=559ee35975f2, moduleTitle=皮肤镜鉴别恶性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=559ee35975f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479439, encodeId=92bf14e9439a6, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳, objectType=article, longId=732189, objectId=8459e3218955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8459e3218955, replyNumber=0, likeNumber=88, createdTime=2022-07-13, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8459e3218955, moduleTitle=Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8459e3218955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479438, encodeId=292514e9438f7, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实, objectType=article, longId=218801, objectId=83d72188016f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83d72188016f, replyNumber=0, likeNumber=93, createdTime=2021-10-20, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83d72188016f, moduleTitle=Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83d72188016f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479437, encodeId=a92d14e9437c4, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=77, createdTime=2021-10-17, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479436, encodeId=5eb614e943639, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Am J Clin Dermatol：不同激光手段治疗非黑素瘤皮肤癌的疗效, objectType=article, longId=217133, objectId=a58c21e133ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58c21e133ab, replyNumber=0, likeNumber=89, createdTime=2021-09-16, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58c21e133ab, moduleTitle=Am J Clin Dermatol：不同激光手段治疗非黑素瘤皮肤癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58c21e133ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479435, encodeId=250114e94350e, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Cancer Discov & Clin Cancer Res ：年龄是黑素瘤治疗耐药性的主要决定因素, objectType=article, longId=202881, objectId=18bd20288146, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18bd20288146, replyNumber=0, likeNumber=78, createdTime=2020-11-05, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18bd20288146, moduleTitle=Cancer Discov & Clin Cancer Res ：年龄是黑素瘤治疗耐药性的主要决定因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18bd20288146)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479434, encodeId=c08b14e943402, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=肢端原位黑素瘤1例, objectType=article, longId=193681, objectId=056f19368145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=056f19368145, replyNumber=0, likeNumber=94, createdTime=2020-05-09, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=056f19368145, moduleTitle=肢端原位黑素瘤1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=056f19368145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479433, encodeId=0b7e14e9433e5, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％, objectType=article, longId=193651, objectId=96f61936511b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96f61936511b, replyNumber=0, likeNumber=95, createdTime=2020-05-09, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96f61936511b, moduleTitle=TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96f61936511b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479432, encodeId=817c14e94324f, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=新型冠状病毒感染肺炎期间黑素瘤患者个人防护专家共识（第一版）, objectType=article, longId=189054, objectId=e7ab1890549f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7ab1890549f, replyNumber=0, likeNumber=64, createdTime=2020-03-02, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7ab1890549f, moduleTitle=新型冠状病毒感染肺炎期间黑素瘤患者个人防护专家共识（第一版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7ab1890549f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479431, encodeId=73f814e943179, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=NEJM：转移性黑素瘤患者胃肠道出血-病例报道, objectType=article, longId=186990, objectId=f3ba186990c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3ba186990c8, replyNumber=0, likeNumber=90, createdTime=2020-02-01, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3ba186990c8, moduleTitle=NEJM：转移性黑素瘤患者胃肠道出血-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3ba186990c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, objectType=article, longId=182548, objectId=646d1825487e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646d1825487e, replyNumber=0, likeNumber=80, createdTime=2019-11-08, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646d1825487e, moduleTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646d1825487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479429, encodeId=432914e942943, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从, objectType=article, longId=179861, objectId=018b1e9861c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=018b1e9861c0, replyNumber=0, likeNumber=71, createdTime=2019-09-24, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=018b1e9861c0, moduleTitle=Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=018b1e9861c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479428, encodeId=513214e94280e, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Nat commun：B细胞带来危机与转机，黑素瘤免疫疗法将何去何从？, objectType=article, longId=179664, objectId=29af1e9664e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29af1e9664e4, replyNumber=0, likeNumber=92, createdTime=2019-09-20, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29af1e9664e4, moduleTitle=Nat commun：B细胞带来危机与转机，黑素瘤免疫疗法将何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29af1e9664e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479427, encodeId=51d914e9427a5, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=CELL：UVB诱导的肿瘤异质性减少黑素瘤的免疫应答, objectType=article, longId=179504, objectId=05401e950465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05401e950465, replyNumber=0, likeNumber=86, createdTime=2019-09-17, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05401e950465, moduleTitle=CELL：UVB诱导的肿瘤异质性减少黑素瘤的免疫应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05401e950465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479426, encodeId=2f7314e94265f, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Stem Cell Res Ther：miR-508-5p通过靶向糖蛋白非转移性黑素瘤蛋白B对人牙髓干细胞牙源性分化的抑制作用, objectType=article, longId=158916, objectId=d3131589166d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3131589166d, replyNumber=0, likeNumber=90, createdTime=2019-01-27, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3131589166d, moduleTitle=Stem Cell Res Ther：miR-508-5p通过靶向糖蛋白非转移性黑素瘤蛋白B对人牙髓干细胞牙源性分化的抑制作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3131589166d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479425, encodeId=004314e942596, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=83, createdTime=2019-01-27, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479424, encodeId=d8d214e942459, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤, objectType=article, longId=156471, objectId=aaca1564e1e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaca1564e1e0, replyNumber=0, likeNumber=109, createdTime=2018-12-24, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaca1564e1e0, moduleTitle=CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaca1564e1e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479423, encodeId=f1ba14e942351, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Adv Healthc Mater：转铁蛋白（Tf）修饰的聚乙二醇化石墨烯（PG）载体携带纳米药物高度靶向治疗脉络膜黑素瘤, objectType=article, longId=144291, objectId=29ec144291d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ec144291d2, replyNumber=0, likeNumber=61, createdTime=2018-07-14, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ec144291d2, moduleTitle=Adv Healthc Mater：转铁蛋白（Tf）修饰的聚乙二醇化石墨烯（PG）载体携带纳米药物高度靶向治疗脉络膜黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ec144291d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479422, encodeId=0be914e942270, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, objectTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, objectType=article, longId=141927, objectId=83be14192e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83be14192e7c, replyNumber=0, likeNumber=89, createdTime=2018-06-30, rootId=0, userName=yuhaisheng_ibp_32061713, userId=4d4d7523220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83be14192e7c, moduleTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83be14192e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑素瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#四环素类抗生素# #黑素瘤#

中南大学湘雅医院彭聪教授团队：揭示四环素类抗生素依拉环素通过促进M1型巨噬细胞极化增强黑素瘤抗PD1免疫治疗疗效的作用和机制

2024-09-22发表于上海

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

皮肤镜鉴别恶性黑素瘤

2022-08-17

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Br J Radiol：老年非黑素瘤皮肤癌患者的短疗程加速放疗耐受性良好，高剂量的效果更佳

2022-07-13

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实

2021-10-20

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2021-10-17

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Am J Clin Dermatol：不同激光手段治疗非黑素瘤皮肤癌的疗效

2021-09-16

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Cancer Discov & Clin Cancer Res ：年龄是黑素瘤治疗耐药性的主要决定因素

2020-11-05

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

肢端原位黑素瘤1例

2020-05-09

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％

2020-05-09

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

新型冠状病毒感染肺炎期间黑素瘤患者个人防护专家共识（第一版）

2020-03-02

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

NEJM：转移性黑素瘤患者胃肠道出血-病例报道

2020-02-01

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据

2019-11-08

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Nat Commun：B细胞带来危机与转机，黑素瘤免疫疗法何去何从

2019-09-24

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Nat commun：B细胞带来危机与转机，黑素瘤免疫疗法将何去何从？

2019-09-20

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

CELL：UVB诱导的肿瘤异质性减少黑素瘤的免疫应答

2019-09-17

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Stem Cell Res Ther：miR-508-5p通过靶向糖蛋白非转移性黑素瘤蛋白B对人牙髓干细胞牙源性分化的抑制作用

2019-01-27

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-01-27

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤

2018-12-24

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Adv Healthc Mater：转铁蛋白（Tf）修饰的聚乙二醇化石墨烯（PG）载体携带纳米药物高度靶向治疗脉络膜黑素瘤

2018-07-14

yuhaisheng_ibp_32061713 (审核中...)

前往app查看评论内容

#黑素瘤#

Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤

2018-06-30

科室
- - 订阅+
  - 更多科室
工具
服务